Introduction {#sec1-0300060519862674}
============

Asthma is the most common chronic disease in childhood. In Western countries, the prevalence of asthma is estimated at up to 10% in children aged ≤5 years.^[@bibr1-0300060519862674]^ Although approximately 50% of children will experience wheezing, shortness of breath, and other asthma-like symptoms at least once before the age of 3 years, only approximately 30% of children will have recurrent symptoms by school age.^[@bibr2-0300060519862674],[@bibr3-0300060519862674]^ The occurrence of wheezing episodes in children is related to multiple allergens, such as dust mites, pets, cockroaches, mice, mold, tobacco smoke, endotoxins, and air pollution.^[@bibr4-0300060519862674][@bibr5-0300060519862674]--[@bibr6-0300060519862674]^ Additionally, a family history of asthma, age, family smoking habits, and total immunoglobulin E (IgE) levels are significantly associated with wheezing episodes in children.^[@bibr5-0300060519862674][@bibr6-0300060519862674]--[@bibr7-0300060519862674]^ Unfortunately, for many reasons, detection of pulmonary function in infants is not reliable. Currently, there is no exact diagnostic method for wheezing episodes. Therefore, new factors for reliable wheezing episodes and prediction of asthma during infancy are required.

One important diagnostic tool for asthma in children is the asthma predictive index (API), but its clinical value remains controversial. In 2010, Castro-Rodriguez first proposed the API as a simple and convenient clinical indicator of asthma in infants and preschool children.^[@bibr2-0300060519862674]^ The API is increasingly used in clinical practice and is approved by various international guidelines.^[@bibr5-0300060519862674],[@bibr6-0300060519862674]^ However, the accuracy of the API for prediction is affected by genetic polymorphism, environmental and socioeconomic factors, sex, race, and family health beliefs.^[@bibr8-0300060519862674][@bibr9-0300060519862674][@bibr10-0300060519862674]--[@bibr11-0300060519862674]^ Moreover, a follow-up study of 1954 children with asthma (aged 7--10 years) showed that the ability of API to predict asthma was relatively weak^[@bibr9-0300060519862674]^ and that it requires improvement.^[@bibr12-0300060519862674],[@bibr13-0300060519862674]^ To be reliable, such improvements require a better understanding of the underlying pathophysiology.

The orosomucoid 1-like 3 (*ORMDL3*) gene, known as ORMDL sphingolipid biosynthesis regulator 3, was found to be a candidate gene for asthma in a genome-wide association study.^[@bibr14-0300060519862674]^ *ORMDL3* expression is stimulated by allergens and cytokines, and mainly occurs in airway epithelial cells.^[@bibr15-0300060519862674]^ *ORMDL3* expression is positively associated with recurrent wheezing in children.^[@bibr16-0300060519862674]^ However, the diagnostic value of *ORMDL3* in children requires further investigation.

Wheezing in children aged ≤5 years is not diagnostic of asthma. Therefore, a reliable test for determining the risk of developing asthma in this population is necessary. This study aimed to assess whether *ORMDL3* expression and environmental and clinical factors are associated with asthma in preschool wheezing children. We detected *ORMDL3* expression levels in children (\<5 years of age) with wheezing episodes who were grouped according to their API results. We also analyzed the predictive value of *ORMDL3* expression on the API, and the correlations between *ORMDL3* expression and sex, age, family history, environmental factors, dietary factors, and other risk factors associated with wheezing episodes. Our results could help determine whether *ORMDL3* is a reliable clinical biomarker for early prediction of asthma in children.

Materials and methods {#sec2-0300060519862674}
=====================

Patient information {#sec3-0300060519862674}
-------------------

This was a retrospective study of consecutive children aged \<5 years who visited the Respiratory Health outpatient clinic and inpatient ward of Renji Hospital (Shanghai, China) between April 2013 and August 2014. The inclusion criteria were (1) wheezing symptoms and lung sounds of expiratory wheezing, and (2) age \<5 years. The exclusion criteria were as follows: (1) other causes of breathing problems, such as foreign bodies in the bronchi, bronchopulmonary dysplasia, gastroesophageal reflux, trachea ring, and congenital heart disease; or (2) other diseases affecting *ORMDL3* expression, such as infectious diseases, autoimmune diseases, hematological diseases, and cancer. The research design was approved by Renji Hospital ethics committee. Written informed consent was obtained for all children from their parents or guardians. Blood samples were collected from enrolled patients. Clinical and demographic data were collected from the medical charts, which contained a routine questionnaire that covered information, such as demographics, medical history, risk factors for asthma, and life habits. The child's legal guardians had to fill out this questionnaire at the first visit to our center. Information, including the API, sex, age, family history, presence of infantile eczema, asthma duration, and rhinitis, was recorded.

API-based classification {#sec4-0300060519862674}
------------------------

We classified the patients based on their API according to classification criteria described in a previous study.^[@bibr17-0300060519862674]^ The positive API (API+) group of patients had ≥four wheezing episodes in the past year and one of the following major risk factors or two of the minor risk factors. The major risk factors were (1) a parental history of asthma, (2) doctor-diagnosed eczema or atopic dermatitis, and (3) sensitization to inhaled allergens. The minor risk factors were (1) food allergen-induced sensitization (including milk, peanuts, and eggs), (2) non-cold wheezing; and (3) ≥4% peripheral blood eosinophils. The negative API (API−) group of patients had one to three wheezing episodes within the past year and no major risk factor or up to two of the minor risk factors. Children without wheezing were defined as the control group (API0). All of the children were routinely tested for IgE using ImmunoCAP analysis (Thermo Fisher Scientific, Waltham, MA, USA). Except for some exceptions, the prick test was not performed. Because the prick test is a commercial test, no other dust was detected and no *Aspergillus* was cultured.

Isolation of individual peripheral blood cells {#sec5-0300060519862674}
----------------------------------------------

Collection and detection of cells were performed on the day after blood collection. A total of 5 mL of venous blood (anti-coagulated with 1.5--2 mg/mL EDTA) was diluted (1:1) with phosphate-buffered saline. An equal volume of diluted blood was slowly added to lymphocyte separation liquid (Ficoll) in a centrifugal tube. Careful attention was paid to maintain a clear interface. The solution was centrifuged (room temperature, 2500 rpm, 20 min), and the mononuclear cell layer (lymphocytes and monocytes) was gently extracted by capillary suction, added to tubes containing 5 mL of phosphate-buffered saline, and mixed fully and evenly. The number of live cells was counted (to ensure that it exceeded 95%). Finally, the cells were centrifuged again (1500 rpm for 10 minutes) and the supernatant was removed.

Real-time quantitative polymerase chain reaction {#sec6-0300060519862674}
------------------------------------------------

Total RNA from peripheral blood mononuclear cells (PBMCs) that were isolated from peripheral blood was extracted by the TRIzol method (TRIzol reagent, \#15596-026; Life Technologies, Gaithersburg, MD, USA). Next, cDNA samples were obtained by reverse transcription using the RevertAid Fist Strand cDNA Synthesis Kit (\#K1622; Thermo Fisher Scientific). *ORMDL3* expression was detected by real-time polymerase chain reaction (PCR) and quantitative PCR (qPCR) amplification (Maxima SYBR Green qPCR Master Mix, \#K0252, Thermo Fisher Scientific). β*-actin* was used as a reference gene. The primer sequences for *ORMDL3* and β*-actin* are shown in [Table 1](#table1-0300060519862674){ref-type="table"}.

###### 

Primers used in this study.

![](10.1177_0300060519862674-table1)

  Gene        Primers
  ----------- ----------------------------
  β-actin-F   5′-ATGATGATATCGCCGCGCTC-3′
  β-actin-R   5′-CCACCATCACGCCCTGG-3′
  ORMDL3-F    5′-CAGCCGCGGGTTGTTACAG-3′
  ORMDL3-R    5′-CCTCTCTGCTGTTCGTGTGG-3′

F: forward; R: reverse.

Statistical analysis {#sec7-0300060519862674}
--------------------

SPSS Statistics for Windows, Wersion 19.0 (IBM, Armonk, NY, USA) was used for statistical analysis. Continuous data that fit a normal distribution are expressed as mean and standard deviation (SD) and were analyzed using one-way analysis of variance and the least significant difference post hoc test. Skewed continuous data are presented as median (range) and were analyzed using the Kruskal--Wallis test and compared pairwise using the S-N-K test. Categorical data are expressed as frequencies and were analyzed using the chi-squared test. To determine the accuracy of *ORMDL3* gene expression as an API+ marker, receiver operating characteristic (ROC) curve analysis was performed. Correlation analysis of *ORMDL3* gene expression with the personal history of patients, family history, and environmental and dietary factors was conducted using Spearman's correlation analysis. P \< 0.05 was considered statistically significant.

Results {#sec8-0300060519862674}
=======

Patients' baseline characteristics {#sec9-0300060519862674}
----------------------------------

A total of 144 consecutive children aged \<5 years from the Renji Hospital inpatient ward and outpatient clinic were included. There were 46 patients in the API+ group (30 months old), 47 in the API− group (months old), and 51 in the API0 group (28 months old). There were no significant differences in sex distribution and age among the three groups. However, the median API score was significantly higher in the API+ group than in the other two groups (P \< 0.001), as expected ([Table 2](#table2-0300060519862674){ref-type="table"}).

###### 

Baseline data of the three API groups.

![](10.1177_0300060519862674-table2)

                                    API+           API-           API0           P value
  --------------------------------- -------------- -------------- -------------- ---------
  n                                 46             47             51             
  Sex ratio (M/F)                   2.07 (31/15)   1.35 (27/20)   0.96 (25/26)   0.19
  Age (months), median (min, max)   30 (19,49)     25 (7,52)      28 (8,54)      0.834
  API, median (min, max)            5 (4,10.5)     1 (1,3)        0 (0,0)        \<0.001

API: asthma predictive index; API+: asthma predictive index (≥4 wheezing episodes); API−: asthma predictive index (1--3 wheezing episodes); API0: asthma predictive index (no wheezing); M: male; F: female; min: minimum; max: maximum.

Individual and family history of patients in the three API groups {#sec10-0300060519862674}
-----------------------------------------------------------------

Because wheezing episodes in children are a multifactorial condition, we conducted comparative analysis of the personal allergy history and family allergy history of the disease according to the API. We found significant differences in the individual history among the three API groups. The occurrence rate of wheezing, eczema, and rhinitis was significantly higher in the API+ groups than in the other two groups (all P \< 0.01) ([Table 3](#table3-0300060519862674){ref-type="table"}). However, a family allergy history was not significantly different among the three groups.

###### 

Personal case history and family history of the different API groups.

![](10.1177_0300060519862674-table3)

                       Total         API+          API−         API0          P value
  -------------------- ------------- ------------- ------------ ------------- ---------
  Individual history                                                          
   Wheezing            93 (64.58%)   46 (100%)     47 (100%)    0             \<0.001
   Eczema              52 (36.11%)   33 (71.74%)   0            19 (37.25%)   \<0.001
   Rhinitis            21 (14.58%)   13 (28.26%)   5 (10.64%)   3 (5.88%)     0.007
  Family history                                                              
   Rhinitis            15 (10.42%)   6 (13.04%)    5 (10.64%)   4 (7.84%)     0.708
   Wheezing            9 (6.25%)     8 (17.39%)    1 (2.13%)    0             0.001
   Dermatitis          9 (6.25%)     2 (4.35%)     4 (8.51%)    3 (5.88%)     0.707

API: asthma predictive index; API+: asthma predictive index (≥4 wheezing episodes); API−: asthma predictive index (1--3 wheezing episodes); API0: asthma predictive index (no wheezing).

*ORMDL3* expression in the different API groups {#sec11-0300060519862674}
-----------------------------------------------

*ORMDL3* expression in PBMCs was analyzed. When we examined relative expression of the *ORMDL3* gene in the API = 4, API = 5, API ≥6, API−, and API0 groups, all three API+ groups (API = 4, API = 5, and API ≥ 6) had significantly higher *ORMDL3* expression than did the API0 (all P \< 0.001) and API− groups (all P \< 0.001). However, no difference in *ORMDL3* expression was observed between the API− and API0 groups ([Figure 1](#fig1-0300060519862674){ref-type="fig"}).

![*ORMDL3* expression was increased in PBMCs of children in the API+ groups (API = 4, API = 5, and API ≥6) compared with the API− or API0 group. The mRNA levels of *ORMDL3* were analyzed by real-time polymerase chain reaction. The numbers of patients for the API0, API−, API = 4, API = 5, and API ≥6 groups were 28, 47, 12, 14, and five, respectively. There was no overlap among the groups. \*\*\*P\<0.001. PBMCs: peripheral blood mononuclear cells; API: asthma predictive index; API+: asthma predictive index (≥4 wheezing episodes); API−: asthma predictive index (1--3 wheezing episodes); API0: asthma predictive index (no wheezing).](10.1177_0300060519862674-fig1){#fig1-0300060519862674}

ROC curve analysis {#sec12-0300060519862674}
------------------

ROC analysis was performed to evaluate the diagnostic value and appropriate cutoff point of *ORMDL3* expression for API+. [Figure 2](#fig2-0300060519862674){ref-type="fig"} shows that the area under the curve (AUC) for *ORMDL3* expression was 0.820 (95% confidence interval, 0.771--0.869). These results strongly suggest that PBMC *ORMDL*3 expression can improve the sensitivity and specificity of diagnostic tests for API+.

![Peripheral blood mononuclear cell *ORMDL*3 expression is a potential biomarker of API+. ROC curve analysis shows the diagnostic power in predicting peripheral blood mononuclear cell *ORMDL3* expression as an API+ marker (AUC: 0.820 \[0.771--0.869\]). API: asthma predictive index; API+: asthma predictive index (≥4 wheezing episodes); ROC: receiver operating characteristic; AUC: area under the curve.](10.1177_0300060519862674-fig2){#fig2-0300060519862674}

Correlation analysis between *ORMDL3* expression and asthma-related variables in children {#sec13-0300060519862674}
-----------------------------------------------------------------------------------------

To analyze the associations of *ORMDL3* expression with the API and wheezing episodes, we evaluated the correlations between *ORMDL3* expression, the API, and other asthma-related variables. There were positive correlations between *ORMDL3* expression and the API (r = 0.447, P \< 0.001), the individual history of patients with infantile eczema (r = 0.499, P \< 0.001), wheezing (r = 0.516, P \< 0.001), and total IgE (r = 0.208, P = 0.002). *ORMDL3* expression was also correlated with environmental factors, including exposure to *Dermatophagoides pteronyssinus* (r = 0.357, P \< 0.001), house dust mites (r = 0.112, P = 0.039), dog fur (r = 0.226, P \< 0.001), and *Aspergillus* (*r* = 0.257, P \< 0.001). Moreover, *ORMDL3* expression levels were negatively correlated with amaranth consumption (r = −0.122, P = 0.024). There were no correlations between *ORMDL3* expression and a family history, age, exposure to cat fur and trees, and streptavidin, as well as dietary factors (milk, egg white, beef, shrimp, crab, cashews, and mango) ([Table 4](#table4-0300060519862674){ref-type="table"}).

###### 

Correlations between *ORMDL3* expression and asthma-related parameters.

![](10.1177_0300060519862674-table4)

                                     Spearman's correlation coefficient (r)   P
  ---------------------------------- ---------------------------------------- ---------
  API                                0.447                                    \<0.001
  Sex                                0.105                                    0.053
  Family history                     −0.043                                   0.432
  Infantile eczema                   0.499                                    \<0.001
  Wheezing                           0.516                                    \<0.001
  Rhinitis                           −0.064                                   0.240
  Age (months)                       0.024                                    0.661
  Total IgE                          0.208                                    0.002
  *Dermatophagoides pteronyssinus*   0.357                                    \<0.001
  House dust mites                   0.112                                    0.039
  Dog fur                            0.226                                    \<0.001
  Cat fur                            0.068                                    0.208
  Trees                              0.029                                    0.598
  *Aspergillus*, streptavidin        0.257                                    \<0.001
  Milk                               0.040                                    0.459
  Egg white                          −0.058                                   0.288
  Beef                               −0.006                                   0.911
  Cashews                            −0.038                                   0.480
  Amaranth                           −0.122                                   0.024
  Crab                               0.016                                    0.774
  Mango                              0.103                                    0.056
  Shrimp                             0.010                                    0.850

API: asthma predictive index; IgE: immunoglobulin E.

Discussion {#sec14-0300060519862674}
==========

Although the API is an important predictive indicator of wheezing episodes in children,^[@bibr2-0300060519862674],[@bibr9-0300060519862674]^ its use in clinical diagnosis remains controversial.^[@bibr12-0300060519862674],[@bibr13-0300060519862674]^ In this study, we investigated whether PBMC *ORMDL3* expression levels are associated with wheezing episodes in children, especially at \<5 years of age. PBMC *ORMDL3* expression in children aged \<5 years was positively associated with their API and was significantly correlated with their personal history of immune diseases (infantile eczema, wheezing, total IgE) and living environment (*D. pteronyssinus*, house dust mites, dog fur, and *Aspergillus*). Therefore, *ORMDL3* expression levels in PBMCs could be used as a clinical indicator of potential development of asthma in children.

Previous studies have shown that *ORMDL3* is closely related to wheezing episodes in children.^[@bibr18-0300060519862674][@bibr19-0300060519862674][@bibr20-0300060519862674]--[@bibr21-0300060519862674]^ In the present study, *ORMDL3* expression was significantly higher in children with API+ compared with those with API− or API0. Additionally, *ORMDL3* expression was positively correlated with an increased API, infantile eczema, wheezing, total IgE levels, *D. pteronyssinus*, house dust mites, dog fur, and *Aspergillus*. *ORMDL3* expression was not correlated with a family history, sex, age, rhinitis, cat fur, trees, and streptavidin, as well as other dietary factors (i.e., milk, egg white, beef, shrimp, crab, cashews, and mango). These results further suggest a close association of *ORMDL3* with recurrent wheezing in children, as well as with environmental (*D. pteronyssinus*, house dust mites, dog fur, and *Aspergillus*) and clinical (infantile eczema, wheezing, and total IgE levels) factors associated with recurrent wheezing.^[@bibr4-0300060519862674],[@bibr22-0300060519862674][@bibr23-0300060519862674][@bibr24-0300060519862674]--[@bibr25-0300060519862674]^ Additionally, *ORMDL3* expression was not associated with common allergies. Taken together, these results suggest that ORMDL3 could be useful for diagnosing wheezing episodes. However, additional studies are necessary to validate this association, especially with allergens that can be found in households. That some allergens are associated with wheezing, while others are not, warrants more in-depth studies.

Numerous studies have shown associations between *ORMDL3* polymorphisms and asthma.^[@bibr18-0300060519862674][@bibr19-0300060519862674]--[@bibr20-0300060519862674],[@bibr26-0300060519862674][@bibr27-0300060519862674][@bibr28-0300060519862674]--[@bibr29-0300060519862674]^ However, the mechanism for involvement of *ORMDL3* in the inflammatory process of asthma in children is not completely understood. Studies in mice showed that *ORMDL3* expression was increased by up to 127 fold in wild-type mice that were exposed to antigens and cytokins.^[@bibr15-0300060519862674],[@bibr30-0300060519862674],[@bibr31-0300060519862674]^ A study based on a house dust mite-induced mouse model of allergic asthma showed that *ORMDL3* overexpression increased production of ceramide, and promoted chronic inflammation and upper airway allergic reactions.^[@bibr32-0300060519862674]^ A recent study showed that higher *ORMDL3* expression induced the p-extracellular-regulated kinase/matrix metalloproteinase-9 pathway, which led to airway remodeling in asthma.^[@bibr33-0300060519862674]^ Two single nucleotide polymorphisms in the promoter region of *ORMDL3* (rs7216389 and rs7216558) are significantly associated with early-onset wheezing episodes in infants and young children.^[@bibr19-0300060519862674][@bibr20-0300060519862674]--[@bibr21-0300060519862674]^ Furthermore, a correlation has been found between rs7216389 and asthma susceptibility in children.^[@bibr26-0300060519862674]^ Such polymorphisms in the promoter region of *ORMDL3* affect *ORMDL3* transcription, which in turn, could increase recurrent wheezing in children.^[@bibr18-0300060519862674]^ These studies support the role of *ORMDL3* expression in asthma. However, further studies are still necessary to determine the exact relationship, which could help for diagnosis and management of asthma.

There are some limitations to our study. Because of the retrospective nature and the small sample size, the detailed phenotypes for each recruited subject are lacking. Additionally, the expected high degree of heterogeneity needs to be considered when interpreting the data. Because of the retrospective nature of the study, we were limited to the data available in the charts. The environmental data were from questionnaires that were filled in by the child's legal guardians at the first visit to our center, and no formal inquiry was made. Furthermore, the exact initial reason for consulting the clinic was not consistently recorded in the charts. Because our study population was pediatric, pulmonary function tests were not performed. IgE levels were qualitatively, not quantitatively, determined. Only *ORMDL3* expression was measured and other genes known to be associated with asthma were not examined. Because of the low number of patients in the API+ group, the correlation between the API and sex, as well as those between *ORMDL3* expression and a family history, age, rhinitis, dietary factors, API score, and other factors, should be further verified. Moreover, this was a retrospective study and we used the API, an imperfect measurement,^[@bibr12-0300060519862674],[@bibr13-0300060519862674]^ which probably introduced bias. Finally, isolating PBMCs represents an additional step, but it is a routine procedure in many hospitals. Therefore, use of more direct methods for measuring *ORMDL3* expression could be useful. Finally, no follow-up is yet available to determine the association of the API and *OMRDL3* expression on the eventual development of asthma. Therefore, to further confirm the relationships among *ORMDL3* expression, the API, and the incidence of wheezing in children, a prospective cohort study with a large sample size is necessary.

In conclusion, *ORMDL3* expression levels are associated with higher API values and other asthma-related factors. Because the reliability of the API is low and pulmonary function tests cannot be performed in young children, adding *ORMDL3* expression to the API could significantly improve our understanding of wheezing episodes in preschool children. This could also improve diagnosis and management of patients.
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